Bristol Myers petitions the Supreme Court in a final bid to prove Gilead's Kite infringed on CAR-T patents
Five years after Juno and Sloan Kettering launched a bitterly fought legal campaign against Gilead’s Kite Pharma, claiming the biotech rival had infringed on its CAR-T patents on the way to launching a pioneering cancer therapy, Bristol Myers Squibb is taking the case all the way to the Supreme Court.
The Juno acquirer says that a Federal Circuit decision that set aside a $1.2 billion verdict in its favor was not just incorrect, it has blighted the field of drug development and created a precedent that threatens the very foundation of innovation in America.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.